Denni M Zborowski

Suggest Changes
Learn More
BACKGROUND Erlotinib is an oral, reversible inhibitor of the HER1/epidermal growth factor receptor (EGFR) tyrosine kinase. A survival advantage for erlotinib compared with placebo was demonstrated in(More)
  • 1